valine has been researched along with Atheroma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Černe, D; Drevenšek, G; Janić, M; Lunder, M; Marc, J; Šabovič, M; Zupan, J | 1 |
| Aono, J; Higaki, J; Horiuchi, M; Inoue, K; Iwai, M; Nagai, T; Nishimura, K; Ogimoto, A; Okayama, H; Suzuki, J | 1 |
2 other study(ies) available for valine and Atheroma
| Article | Year |
|---|---|
The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Diet, Atherogenic; Drug Therapy, Combination; Female; Guinea Pigs; Heptanoic Acids; Interleukin-1beta; Male; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Protective Agents; Pyrroles; Tetrazoles; Valine; Valsartan | 2014 |
Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Carotid Artery Diseases; Carotid Artery, Common; CD36 Antigens; Disease Models, Animal; Disease Progression; Focal Adhesion Kinase 1; Gene Deletion; JNK Mitogen-Activated Protein Kinases; Lipids; Lipoproteins, LDL; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Plaque, Atherosclerotic; Receptor, Angiotensin, Type 1; Rupture, Spontaneous; Superoxides; Tetrazoles; Time Factors; Valine; Valsartan | 2012 |